Skip to main content
    N

    Nektar Therapeutics (NKTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $36.44
    -0.83 (-2.23%)

    Market Cap: $1.27B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nektar Therapeutics (NKTR) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Nektar Therapeutics reported revenue of $55.23M for the fiscal year ended Dec 31, 2025, down 43.9% from the year before. That year, net income was -$164.08M with a net margin of -297.1%, operating cash flow was -$208.51M and free cash flow was -$208.68M. The quarter ended Sep 30, 2026 had revenue of $9.39M and net income of -$55.65M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue fell from $165.44M, a compound annual decline of 11.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$55.23M-43.9%100.0%-253.7%-297.1%
    Dec 2024$98.43M+9.2%68.8%-106.9%-120.9%
    Dec 2023$90.12M-2.1%62.5%-292.6%-306.3%
    Dec 2022$92.06M-9.7%76.5%-408.6%-400.0%
    Dec 2021$101.91M-33.4%75.6%-437.8%-514.0%
    Dec 2020$152.91M+33.4%87.3%-278.0%-290.6%
    Dec 2019$114.62M-90.4%81.4%-383.9%-384.5%
    Dec 2018$1.19B+287.8%98.0%57.6%57.1%
    Dec 2017$307.71M+86.0%90.1%-19.4%-31.4%
    Dec 2016$165.44MN/A81.7%-68.2%-92.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$55.23M$98.43M$90.12M$92.06M$101.91M$152.91M$114.62M$1.19B$307.71M$165.44M
    Cost of revenue$0$30.69M$33.77M$21.64M$24.90M$19.48M$21.37M$24.41M$30.55M$30.21M
    Gross profit$55.23M$67.74M$56.35M$70.42M$77.01M$133.44M$93.24M$1.17B$277.16M$135.22M
    Research and development$117.33M$120.91M$114.16M$218.32M$400.27M$408.68M$434.57M$399.54M$268.46M$203.80M
    Operating income-$140.10M-$105.20M-$263.68M-$376.17M-$446.10M-$425.11M-$440.04M$687.93M-$59.64M-$112.86M
    Net income-$164.08M-$118.96M-$276.06M-$368.20M-$523.84M-$444.44M-$440.67M$681.31M-$96.69M-$153.52M
    EBITDAN/AN/AN/A-$332.26MN/A-$388.70M-$391.94M$736.37M-$40.38M-$95.12M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$9.39M$10.13M$10.86M$21.81M$11.79M$11.18M$10.46M$29.18M$24.12M$23.49M$21.64M$23.89M
    Gross profit$9.39M$10.13M$10.86M$21.81M$11.79M$11.18M$10.46M$21.20M$19.69M$13.75M$13.11M$16.60M
    Operating income-$57.80M-$42.34M-$39.05M-$27.66M-$31.67M-$36.23M-$44.53M$14.35M-$34.34M-$49.77M-$35.43M-$33.51M
    Net income-$55.65M-$40.62M-$44.90M-$36.08M-$35.52M-$41.59M-$50.88M$7.26M-$37.06M-$52.36M-$36.80M-$42.08M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $20.50M exceeded cash and equivalents by $5.38M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$280.41M$303.85M$398.03M$710.60M$1.12B$1.54B$1.98B$2.15B$508.87M$568.87M
    Current assets$266.27M$261.29M$330.70M$545.97M$795.58M$1.14B$1.42B$1.44B$326.82M$425.95M
    Cash and equivalents$15.12M$44.25M$35.28M$88.23M$25.22M$198.96M$96.36M$194.91M$4.76M$59.64M
    Total liabilities$190.57M$243.11M$267.05M$343.96M$437.68M$461.47M$571.97M$432.60M$421.04M$480.75M
    Short-term debt$20.50M$19.87M$19.26M$18.67M$17.44M$13.91M$252.89M$0$31.99M$5.82M
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$246.95M$245.21M$243.46M
    Shareholder equity$89.83M$60.74M$130.99M$366.64M$679.51M$1.08B$1.41B$1.72B$87.83M$88.13M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.04B$1.10B$763.27M$280.41M$301.35M$207.53M$256.24M$303.85M$307.97M$343.33M$396.01M$398.03M
    Total liabilities$187.53M$192.01M$187.06M$190.57M$216.26M$231.75M$242.50M$243.11M$259.08M$263.65M$269.31M$267.05M
    Cash and equivalents$34.69M$39.27M$149.58M$15.12M$41.03M$42.99M$38.89M$44.25M$30.11M$27.94M$48.64M$35.28M
    Shareholder equity$849.72M$903.12M$576.22M$89.83M$85.09M-$24.21M$13.74M$60.74M$48.88M$79.69M$126.70M$130.99M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$208.51M-$175.71M-$192.61M-$304.01M-$412.66M-$313.29M-$328.68M$718.21M-$80.41M-$117.02M
    Capital expenditures$171.00K$1.47M$865.00K$5.68M$14.99M$7.26M$26.29M$14.24M$9.68M$6.39M
    Free cash flow-$208.68M-$177.18M-$193.47M-$309.68M-$427.65M-$320.55M-$354.97M$703.98M-$90.09M-$123.42M
    Share repurchases$1.15M$3.00M$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$1.20M$142.57M$139.56M$365.83M$202.78M$496.21M$206.89M-$1.38B-$28.81M-$82.40M
    Financing cash flow$180.57M$42.12M$30.00K$1.51M$36.24M-$80.35M$23.36M$851.97M$54.39M$203.62M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$71.93M-$75.77M-$44.30M-$64.96M-$48.76M-$45.74M-$49.05M-$46.19M-$43.93M-$37.70M-$47.89M-$47.05M
    Capital expenditures$398.00K$94.00K$18.00K$18.00K$114.00K$37.00K$2.00K$459.00K$666.00K$186.00K$157.00K$237.00K
    Free cash flow-$72.33M-$75.86M-$44.32M-$64.98M-$48.88M-$45.77M-$49.05M-$46.65M-$44.60M-$37.89M-$48.05M-$47.28M
    Last 12 quarters

    Frequently Asked Questions About NKTR

    What is Nektar Therapeutics' annual revenue?

    Nektar Therapeutics reported revenue of $55.23M for the fiscal year ended Dec 31, 2025.

    How fast is Nektar Therapeutics' revenue growing?

    Revenue was down 43.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -15.7%.

    Is Nektar Therapeutics profitable?

    No. Nektar Therapeutics reported net income of -$164.08M for the fiscal year ended Dec 31, 2025, with a net margin of -297.1%.

    How much free cash flow does NKTR generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$208.51M minus capital expenditures of $171.00K produced free cash flow of -$208.68M.

    How much debt does Nektar Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $20.50M and cash and equivalents of $15.12M.